EPIK-B2: A phase III study of alpelisib (ALP) as maintenance therapy with trastuzumab (T) and pertuzumab (P) in patients (pts) with PIK3CA-mutated (mut) human epidermal growth factor receptor-2-positive (HER2+) advanced breast cancer (ABC) Meeting Abstract

  

Authors:	Hurvitz, S. A.; Chia, S. K. L.; Ciruelos, E. M.; Hu, X.; Im, S. A.; Janni, W.; Jerusalem, G.; Lacouture, M.; O'Regan, R.; Rugo, H. S.; Yap, Y. S.; Ghaznawi, F.; Han, Y.; Su, F.; Chandarlapaty, S.
Abstract Title:	EPIK-B2: A phase III study of alpelisib (ALP) as maintenance therapy with trastuzumab (T) and pertuzumab (P) in patients (pts) with PIK3CA-mutated (mut) human epidermal growth factor receptor-2-positive (HER2+) advanced breast cancer (ABC)
Meeting Title:	ESMO Virtual Congress 2020
Journal Title:	Annals of Oncology
Volume:	31
Issue:	Suppl. 4
Meeting Dates:	2020 Sep 19-21/Oct 16-18
Meeting Location:	Virtual
ISSN:	0923-7534
Publisher:	Oxford University Press
Date Published:	2020-09-01
Start Page:	S389
End Page:	S390
Language:	English
ACCESSION:	WOS:000573469100352
DOI:	10.1016/j.annonc.2020.08.454
PROVIDER:	wos
Notes:	Meeting Abstract: 352TiP -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/172712